Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Baker S, et al. Among authors: alexander as. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):849-855. doi: 10.1016/j.ijrobp.2022.08.026. Epub 2022 Oct 24. Int J Radiat Oncol Biol Phys. 2022. PMID: 36302495 Clinical Trial.
Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
Truong PT, Jones SO, Kader HA, Wai ES, Speers CH, Alexander AS, Olivotto IA. Truong PT, et al. Among authors: alexander as. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):357-64. doi: 10.1016/j.ijrobp.2008.04.034. Int J Radiat Oncol Biol Phys. 2009. PMID: 18676091
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. Whelan TJ, et al. Lancet. 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813635 Clinical Trial.
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson RA. Baker S, et al. Among authors: alexander as. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):617-626. doi: 10.1016/j.ijrobp.2022.05.033. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35667528 Clinical Trial.
73 results